Decreased serum carnitine in valproate induced Reye syndrome
- 1 November 1982
- journal article
- case report
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 139 (3), 185-186
- https://doi.org/10.1007/bf01377353
Abstract
A 3-year-old girl developed acute liver disease after treatment with valproate for 6 months. She developed the typical features of Reye syndrome. Serum free carnitine was decreased as well as 3-keto-valproic acid, the main metabolite of β-oxidation of valproate. The serum valproate concentration was at the upper limit of the therapeutic range. The possible importance of carnitine in the pathogenesis of valproate induced liver disease is discussed.Keywords
This publication has 15 references indexed in Scilit:
- Amino acid pattern in Reye syndrome: Comparison with clinically similar entitiesThe Journal of Pediatrics, 1981
- Concentration of Metabolites of Valproic Acid in Plasma of Epileptic PatientsEpilepsia, 1981
- FATAL HEPATIC FAILURE AND SODIUM VALPROATEThe Lancet, 1980
- Systemic Carnitine Deficiency — A Treatable Inherited Lipid-Storage Disease Presenting as Reye's SyndromeNew England Journal of Medicine, 1980
- ACUTE LIVER DISEASE ASSOCIATED WITH SODIUM VALPROATEThe Lancet, 1980
- Systemic carnitine deficiency simulating recurrent Reye syndromeThe Journal of Pediatrics, 1980
- Fatal reye‐like syndrome associated with valproic acidAnnals of Neurology, 1980
- Reye-like syndrome associated with valproic acid therapyThe Journal of Pediatrics, 1979
- Acute Hepatic Failure Associated with the Use of Sodium ValproateNew England Journal of Medicine, 1979
- Production of the Features of Reye's Syndrome in Rats with 4-Pentenoic AcidPediatric Research, 1975